Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioXcel Therapeutics (BTAI) Assets (2022 - 2025)

Historic Assets for BioXcel Therapeutics (BTAI) over the last 4 years, with Q3 2025 value amounting to $44.8 million.

  • BioXcel Therapeutics' Assets fell 838.58% to $44.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $44.8 million, marking a year-over-year decrease of 838.58%. This contributed to the annual value of $38.3 million for FY2024, which is 4798.24% down from last year.
  • As of Q3 2025, BioXcel Therapeutics' Assets stood at $44.8 million, which was down 838.58% from $25.8 million recorded in Q2 2025.
  • In the past 5 years, BioXcel Therapeutics' Assets registered a high of $248.2 million during Q2 2022, and its lowest value of $25.8 million during Q2 2025.
  • Its 4-year average for Assets is $116.6 million, with a median of $82.3 million in 2024.
  • In the last 5 years, BioXcel Therapeutics' Assets plummeted by 6419.68% in 2023 and then tumbled by 838.58% in 2025.
  • Quarter analysis of 4 years shows BioXcel Therapeutics' Assets stood at $205.9 million in 2022, then plummeted by 64.2% to $73.7 million in 2023, then tumbled by 47.98% to $38.3 million in 2024, then increased by 16.83% to $44.8 million in 2025.
  • Its Assets was $44.8 million in Q3 2025, compared to $25.8 million in Q2 2025 and $38.6 million in Q1 2025.